TY - JOUR
T1 - Dupilumab for atopic dermatitis
T2 - a real-world Portuguese multicenter retrospective study
AU - Torres, T.
AU - Paiva-Lopes, M. J.
AU - Gonçalo, M.
AU - Claro, C.
AU - Oliveira, M.
AU - Gomes, J.
AU - Vieira, A. P.
AU - Amoedo, P.
AU - Alpalhão, M.
AU - Nogueira, M.
AU - Santiago, F.
AU - Henrique, M.
AU - Amaro, C.
AU - Esteves, T.
AU - Alves, J.
AU - Cerejeira, D.
AU - Mendes-Bastos, P.
AU - Pestana, M.
AU - Ramos, L.
AU - Rocha, J.
AU - Carvalho, R.
AU - Teixeira, L.
AU - Selores, M.
AU - Mota, A.
AU - Filipe, P.
N1 - Funding Information:
Tiago Torres has received research grants and/or consulting fees from AbbVie, Almirall, Amgen, Arena Pharmaceuticals, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, LEO Pharma, MSD, Novartis, Pfizer, Samsung-Bioepis, Sandoz and Sanofi.
Funding Information:
Maria João Paiva-Lopes has received research grants and/or consulting fees from AbbVie, Almirall, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, and Sanofi.
Publisher Copyright:
© 2022 Taylor & Francis Group, LLC.
PY - 2022/1
Y1 - 2022/1
N2 - Introduction: Atopic dermatitis (AD) is a difficult-to-treat inflammatory skin disease with a high impact on patients’ quality of life. Dupilumab, an IL-4 and IL-13 inhibitor, was the first monoclonal antibody approved for the treatment of moderate-to-severe AD and is currently approved in patients aged 6 or older. Methods: This is a nationwide, multicenter, retrospective, 48-week study designed by the Portuguese Group of AD to assess real-world efficacy and safety of dupilumab for the treatment of AD. Results: A total of 169 patients were enrolled, with a mean disease duration of 22.75 (±11.98) years. The percentage of patients achieving an improvement of at least 75% in Eczema Area and Severity Index (EASI) compared to baseline (EASI75 response) at weeks 12 and 48 was 67.6% and 74.1%, respectively. In the same timepoints, 25.0% and 44.1% achieved an EASI90 response. Patient-reported outcome measures also improved throughout the study period. Regarding safety, 32.0% of the patients developed adverse events, with conjunctivitis (26.6%), persistent facial erythema (4.7%), and arthritis/arthralgia (3.6%) as the more frequently reported. Conclusion: Data from real-world populations are crucial to guide clinicians in their daily decisions. This study provides data demonstrating that dupilumab is an effective and safe therapeutic option for AD.
AB - Introduction: Atopic dermatitis (AD) is a difficult-to-treat inflammatory skin disease with a high impact on patients’ quality of life. Dupilumab, an IL-4 and IL-13 inhibitor, was the first monoclonal antibody approved for the treatment of moderate-to-severe AD and is currently approved in patients aged 6 or older. Methods: This is a nationwide, multicenter, retrospective, 48-week study designed by the Portuguese Group of AD to assess real-world efficacy and safety of dupilumab for the treatment of AD. Results: A total of 169 patients were enrolled, with a mean disease duration of 22.75 (±11.98) years. The percentage of patients achieving an improvement of at least 75% in Eczema Area and Severity Index (EASI) compared to baseline (EASI75 response) at weeks 12 and 48 was 67.6% and 74.1%, respectively. In the same timepoints, 25.0% and 44.1% achieved an EASI90 response. Patient-reported outcome measures also improved throughout the study period. Regarding safety, 32.0% of the patients developed adverse events, with conjunctivitis (26.6%), persistent facial erythema (4.7%), and arthritis/arthralgia (3.6%) as the more frequently reported. Conclusion: Data from real-world populations are crucial to guide clinicians in their daily decisions. This study provides data demonstrating that dupilumab is an effective and safe therapeutic option for AD.
KW - Atopic dermatitis
KW - biologics
KW - dupilumab
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=85127774869&partnerID=8YFLogxK
U2 - 10.1080/09546634.2022.2035309
DO - 10.1080/09546634.2022.2035309
M3 - Article
C2 - 35083945
AN - SCOPUS:85127774869
SN - 0954-6634
VL - 33
SP - 2554
EP - 2559
JO - Journal of Dermatological Treatment
JF - Journal of Dermatological Treatment
IS - 5
ER -